Thibaud Jourdan

Université Libre de Bruxelles — Belgium

Medicine · Health Sciences

5h-index389citations14works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(5), Chronic Lymphocytic Leukemia Research(5), Cancer Cells and Metastasis(4), Antimicrobial Resistance in Staphylococcus(2), Streptococcal Infections and Treatments(2)

Publications14 total

When loss of protection does not permit attack: Distinguishing acts harmful to the enemy from the notion of military objectives
International Review of the Red Cross·2026Open Access
Abstract 5610: BAY 2927088: a novel treatment option for patients with NSCLC with <i>HER2</i> mutations
Cancer Research·2025
Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy
Cancer Research·2022· 2 cited
Identification of a neural development gene expression signature in colon cancer stem cells reveals a role for EGR2 in tumorigenesis
iScience·2022· 26 citedOpen Access
RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence
iScience·2021· 13 citedOpen Access
RNA-Sequencing of Long-Term Label-Retaining Colon Cancer Stem Cells Identifies Novel Regulators of Quiescence
2021Open Access
Identification of a Nervous System Gene Expression Signature in Colon Cancer Stem Cells Reveals a Role for Neural Crest Regulators <i>EGR2</i> and <i>SOX2</i> in Tumorigenesis
2021Open Access
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Blood Advances·2020· 39 citedOpen Access
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS
Hematological Oncology·2019· 2 cited
Abstract 154: The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib
Cancer Research·2017· 3 cited
COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS
Hematological Oncology·2017Open Access
The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents
Blood·2016· 4 cited
Contribution of Each of Four Superantigens to<i>Streptococcus equi</i>-Induced Mitogenicity, Gamma Interferon Synthesis, and Immunity
Infection and Immunity·2010· 49 citedOpen Access
Genomic Evidence for the Evolution of Streptococcus equi: Host Restriction, Increased Virulence, and Genetic Exchange with Human Pathogens
PLoS Pathogens·2009· 251 citedOpen Access

Frequent Co-authors

Martin Lange(10), Melanie Berthold(7), Chiara Tarantelli(5), Eugenio Gaudio(5), Filippo Spriano(5), Ivo Kwee(5), Andrea Rinaldi(5), Davide Rossi(5), Emanuele Zucca(5), Oliver Politz(5), Francesco Bertoni(5), Alberto J. Arribas(4), Anastasios Stathis(4), Joseph L. Regan(4), Dirk Schumacher(4), Stephanie Staudte(4), Andreas Steffen(4), Ralf Lesche(4), Joern Toedling(4), Johannes Haybaeck(4)